Bringing the very best science and medicine to our best equine friends

NEWS

KindredBio to Announce Third Quarter 2014 Financial Results

Company to Hold Conference Call and Webcast at 4:30 p.m. Eastern Time on Thursday, November 13, 2014 SAN FRANCISCO, California. (November 6, 2014) – Kindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company focused on saving and improving the lives of pets, announced today that it will release its third quarter 2014 financial results on November 13, 2014 after the market close. The Company will host a conference call at 4:30 p.m. Eastern Time that day. Interested parties may access the call by dialing toll-free (855) 433-0927 from the US, or (484) 756-4262 internationally, and using conference ID 32324288. The call …

Continue Reading

Kindred Biosciences Announces Second Quarter 2014 Financial Results

San Francisco, CA (August 13, 2014) Kindred Biosciences, Inc. (NASDAQ: KIN) today announced financial results for the quarter ended June 30, 2014. Conference Call and Webcast at 4:30 p.m. Eastern / 1.30 p.m. Pacific “It is an exciting time for KindredBio as we develop our broad portfolio of drug candidates,” stated Richard Chin, M.D., President and Chief Executive Officer of KindredBio. “We currently anticipate the topline results from our pivotal study of CereKin shortly. The fact that we completed the entire study from start to finish in only 12 months, and on budget, is a testament to the quality and …

Continue Reading

Kindred Biosciences Announces First Quarter 2014 Financial Results and Completion of Enrollment in CereKin Pivotal Study

San Francisco, CA (May 12, 2014) Kindred Biosciences, Inc. (NASDAQ: KIN) today announced financial results for the quarter ended March 31, 2014. In addition, KindredBio announced that it has completed enrollment in KB010, its pivotal study for CereKinTM (diacerein).

Continue Reading

KindredBio to Announce First Quarter 2014 Financial Results on Monday, May 12th

Company to Hold Conference Call and Webcast at 4:30 p.m. Eastern Time that Day SAN FRANCISCO, California. (May 6, 2014) – Kindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company focused on saving and improving the lives of pets, announced today that it will release its first quarter 2014 financial results on May 12, 2014 after the market close. The Company will host a conference call at 4:30 p.m. Eastern Time that day.

Continue Reading

KindredBio Announces Closing of Public Offering and Exercise of Over-Allotment Option

SAN FRANCISCO, California. (April 8, 2014) – Kindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company focused on saving and improving the lives of pets, today announced the closing of its public offering of 3,450,000 shares of its common stock, including 450,000 shares sold pursuant to the exercise in full by the underwriters of their over-allotment option, at a public offering price of $18.00 per share. KindredBio estimates net proceeds from the offering to be approximately $58.1 million, after deducting underwriting discounts and commissions and estimated offering expenses.

Continue Reading

Kindred Bio Announces Pricing of Public Offering

SAN FRANCISCO, California. (April 3, 2014) – Kindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company focused on saving and improving the lives of pets, today announced the pricing of its public offering of 3,000,000 shares of its common stock at a public offering price of $18.00 per share, for a total offering amount of $54,000,000 before deducting underwriting discounts and commissions and estimated offering expenses payable by KindredBio, upsized from the previously announced public offering of $50,000,000. KindredBio has granted to the underwriters a 30-day option to purchase up to an additional 450,000 shares of its common stock at the …

Continue Reading

KindredBio and X-Body Announce an Exclusive Collaboration for Discovery of Antibodies for Companion Animal Health

SAN FRANCISCO, CA and WALTHAM, MA, USA. (March 31, 2014) – Kindred Biosciences, Inc. (NASDAQ: KIN) and X-Body Biosciences (X-Body) jointly announced today an exclusive alliance in which X-Body will discover fully canine, feline, and equine antibodies for companion animal health, and KindredBio will develop and commercialize these antibodies. KindredBio will provide an upfront payment, research funding, milestones, and royalties, and X-Body will exclusively license these antibodies to KindredBio.

Continue Reading